Labcorp Adds High Sensitivity Antigen Test to Screen for Active COVID-19 Infection

Rhea-AI Summary

Labcorp (NYSE: LH) has launched a new laboratory-based antigen test to help determine active COVID-19 infections. Developed by DiaSorin, this test requires a doctor's order and is conducted using a nasal or nasopharyngeal swab. Results are typically available within 24-48 hours. Labcorp emphasizes that while PCR tests remain the gold standard for COVID-19 diagnosis, antigen tests are an important tool for assessing infection status. The test has been made available in the U.S. following FDA notification on October 26, 2020.

Positive

• Launch of a new high-sensitivity antigen test for COVID-19.
• Results available within 24-48 hours, improving patient access to information.

Negative

• None.

Labcorp (NYSE: LH), a leading global life sciences company, today announced the availability of a new laboratory-based antigen test that will help doctors determine if an individual is actively infected with COVID-19.

Photo courtesy of Labcorp (Photo: Business Wire)

Developed by DiaSorin, the antigen test is available to patients through a doctor’s order and allows for testing to determine if individuals are still infected with and could spread COVID-19. The test is performed by a doctor or other healthcare provider using a nasal or nasopharyngeal swab to collect a sample and is then picked up and processed by Labcorp. Results are available on average within 24-48 hours from time of pick up.

“This new high-sensitivity antigen test is another example of Labcorp’s commitment to providing people with the information they need to make important health decisions,” said Dr. Brian Caveney, chief medical officer and president, Labcorp Diagnostics. “PCR tests are still considered the gold standard in diagnosing COVID-19, as they are able to detect the smallest traces of the virus. However, an antigen test is an additional tool to help individuals know if they could still be carrying the virus or if they are safe to resume work and life activities.”

According to the Centers for Disease Control and Prevention (CDC), antigen tests can be used in a variety of testing strategies to respond to the COVID-19 pandemic and are helpful in determining whether a person diagnosed with COVID-19 remains infectious.

Labcorp continues to recommend that individuals follow health guidelines, including wearing a mask in public, socially distancing, frequently washing hands and avoiding large groups, and receiving a COVID-19 vaccine as availability increases and the CDC guidance expands to more eligible groups. For more information about Labcorp’s COVID-19 response and testing options, visit Labcorp’s COVID-19 microsite.

The DiaSorin LIAISON® SARS-CoV-2 Ag antigen test has been made available to the U.S. market following notification to the U.S. Food and Drug Administration (FDA) on October 26, 2020 pursuant to the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency (Revised) and published May

FAQ

What is the new COVID-19 test launched by Labcorp (LH)?

Labcorp has launched a new laboratory-based antigen test developed by DiaSorin to determine active COVID-19 infections.

How long does it take to get results from Labcorp's new antigen test?

Results from Labcorp's new antigen test are typically available within 24-48 hours.

What is the significance of Labcorp's new antigen test?

The antigen test is a complementary tool alongside PCR tests, helping individuals assess if they are currently infected with COVID-19.

When was Labcorp's new COVID-19 antigen test made available?

The antigen test was made available to the U.S. market following FDA notification on October 26, 2020.